ResearcherPennsylvania State UniversityNo recent work listed
Christopher S. Hollenbeak
Matched on ORCID iD 0000-0002-3362-814X; OpenAlex author ID A5023382490. Sources: OpenAlex.
Their work
- Papers
- 11 (first author 6, last author 1)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2016: 2 papers · 2017: 4 papers · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: none · 2022: 1 paper
Papers 11
- Do-Not-Resuscitate Orders and Outcomes for Patients with Pancreatic Cancer. Last author DOI 10.1089/pancan.2022.0006↗
- Rural-Urban Disparities in Pancreatic Cancer Stage of Diagnosis: Understanding the Interaction With Medically Underserved Areas. First author DOI 10.1111/jrh.12498↗
- Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resected pancreatic cancer. Co-author DOI 10.1007/s00464-017-5937-7↗
- Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer. First author DOI 10.1007/s11605-018-3730-0↗
- Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. Co-author DOI 10.1016/j.ijsu.2018.01.043↗
- Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer. First author DOI 10.1016/j.amjsurg.2016.08.015↗
- Greater lymph node retrieval and lymph node ratio impacts survival in resected pancreatic cancer. First author DOI 10.1016/j.jss.2017.06.076↗
- Utilization and trends in palliative therapy for stage IV pancreatic adenocarcinoma patients: a U.S. population-based study. Co-author DOI 10.21037/jgo.2017.06.01↗
- Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage I-III pancreatic adenocarcinoma: a U.S. population study. First author DOI 10.21037/jgo.2017.07.04↗
- Time to the initiation of adjuvant chemotherapy does not impact survival in patients with resected pancreatic cancer. Co-author DOI 10.1002/cncr.30163↗
- Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base. First author DOI 10.1016/j.ijsu.2016.08.523↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Katelin Anne Mirkin · 9 shared papers, 2016–2018 · strength 0.99
- Paper Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer. DOI 10.1007/s11605-018-3730-0↗
- Paper Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resecte… DOI 10.1007/s00464-017-5937-7↗
- Paper Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. DOI 10.1016/j.ijsu.2018.01.043↗
- Joyce Y. Wong · 9 shared papers, 2016–2018 · strength 0.99
- Paper Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer. DOI 10.1007/s11605-018-3730-0↗
- Paper Minimally invasive surgical approaches offer earlier time to adjuvant chemotherapy but not improved survival in resecte… DOI 10.1007/s00464-017-5937-7↗
- Paper Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. DOI 10.1016/j.ijsu.2018.01.043↗
- Niraj Jaysukh Gusani · 3 shared papers, 2017–2022 · strength 0.51
- Paper Do-Not-Resuscitate Orders and Outcomes for Patients with Pancreatic Cancer. DOI 10.1089/pancan.2022.0006↗
- Paper Rural-Urban Disparities in Pancreatic Cancer Stage of Diagnosis: Understanding the Interaction With Medically Underserv… DOI 10.1111/jrh.12498↗
- Paper Trends in utilization of neoadjuvant therapy and short-term outcomes in resected pancreatic cancer. DOI 10.1016/j.amjsurg.2016.08.015↗
- Joel E. Segel · 2 shared papers, 2020–2022 · strength 0.41
- Qiang Hao · 1 shared paper, 2022 · strength 0.22
- Audrey Stokes Kulaylat · 1 shared paper, 2017 · strength 0.10
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.